Zinc finger motifWIKIMEDIA, THOMAS SPLETTSTOESSERIn a first, a man has received a therapy aimed at editing the genes inside his body. The Associated Press reports that 44-year-old Brian Madeux, who has a genetic condition called Hunter syndrome, was treated with zinc finger nucleases (ZFNs) targeting a deficient gene in his liver on Monday (November 13) at a hospital in Oakland, California.
“This is the first time someone could have a new gene put into their liver,” Sangamo President and CEO Sandy Macrae told The Scientist in May. “It’s a privilege and a responsibility to do” these trials.
“It’s kind of humbling,” Madeux tells the Associated Press about being the first to receive such an in vivo gene-editing treatment. “I’m willing to take that risk. Hopefully it will help me and other people.”
Hunter syndrome is a rare condition in which people lack an enzyme that breaks down complex polysaccharides. To correct it, ZFNs are directed to cut the gene for albumin in liver cells, where the functional copy of the enzyme’s gene is then incorporated. The therapy was developed by California-based Sangamo Therapeutics.
Compared to genome ...
